WINTERTHUR, Switzerland--(BUSINESS WIRE)--Cardiola AG announced today that the Company’s CE-Marked m.pulse® Muscular CounterPulsation (“MCP”)-based system demonstrated “an immediate improvement of cardiac output with non-invasive means” in a patient population of advanced yet stable chronic heart failure. The effects could be shown in 22 patients over three consecutive days.